Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Therapeutic peptides revisited

Abstract

After a roller coaster ride of successes and failures, new discovery technologies and advances in manufacturing promise a brighter future for peptides in human therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: US patient populations for some peptide therapies in development.
Figure 2: Manufacturing costs for bulk peptide production (over 100 kg).
Figure 3

References

  1. http://www.genosys.com/prod01.html; http://www.anaspec.com/custom_fset.html.

  2. Kelly, W.S. Therapeutic peptides: the devil is in the details. Bio/Technology 14, 28—31 ( 1996).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Latham, P. Therapeutic peptides revisited. Nat Biotechnol 17, 755–757 (1999). https://doi.org/10.1038/11686

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/11686

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing